<DOC>
	<DOCNO>NCT02606123</DOCNO>
	<brief_summary>The study consist 2 part : Part I ( Dose Escalation ) Part II ( Dose Expansion ) . In Part I , patient participate single , multiple , long-term dosing period use EPI-506 determine safety , pharmacokinetics , maximum tolerate dose , preliminary indication anti-tumor activity . Part I open-label , adaptive 3 + 3 design , dose-escalation study . Approximately six dose level EPI-506 study , begin 80 mg/day . Enrolled patient may allow escalate subsequent dose cohort initial twelve week . In Part II , 3 patient population ; post-abiraterone metastatic castration-resistant prostate cancer ( mCRPC ) enzalutamide-naïve , post-enzalutamide mCRPC abiraterone-naïve , post-abiraterone enzalutamide mCRPC study recommended Phase 2 dose ( RP2D ) determine Part I 12 week daily dose . Approximately 120 patient ( 40 cohort ) enrol .</brief_summary>
	<brief_title>Safety Anti-Tumor Study Oral EPI-506 Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<mesh_term>Genital Neoplasms , Male</mesh_term>
	<mesh_term>Genital Diseases , Male</mesh_term>
	<criteria>Adenocarcinoma Prostate Metastatic Disease least one lesion bone scan and/or soft tissue CT/MRI Demonstrated progression abiraterone and/or enzalutamide Demonstrated PSA progression within 12 week study participation Castrate testosterone level screen continue Luteinizing hormonereleasing hormone ( LHRH ) therapy Eastern Cooperative Oncology Group ( ECOG ) score 01 Asymptomatic mildly symptomatic Candidates cytotoxic chemotherapy Received one line chemotherapy Received one treatment course enzalutamide abiraterone Inadequate washout prohibit hormonally active agent prior treatment prostate cancer ( PCa ) Known intracerebral disease brain mets Spinal cord compression within 6 month Prior treatment investigative androgen receptor ( AR ) agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
</DOC>